Alterity Therapeutics (ATHE) FCF Margin (2016 - 2019)

Alterity Therapeutics' FCF Margin history runs 4 years deep, the most recent figure standing at 142.67% for Q4 2019.

• On a quarterly basis, FCF Margin rose 44365.0% year-over-year to 142.67% in Q4 2019; TTM through Dec 2019 was 315.93%, a 1609.0% increase from a year earlier, with the FY2024 full-year figure at 12.08%, changed N/A from the prior year.
• FCF Margin grew to 142.67% in Q4 2019 per ATHE's latest filing, from 300.98% in the prior quarter.
• Across five years, FCF Margin topped out at 1027.32% in Q4 2017 and bottomed at 300.98% in Q4 2018.
• The 4-year median for FCF Margin is 54.23% (2019), against an average of 208.7%.
• Across the five-year window, FCF Margin soared 106154 bps in 2017 and slumped 132830 bps in 2018, its largest moves.
• Year by year, FCF Margin stood at 34.22% in 2016, then surged by 3102 bps to 1027.32% in 2017, then sank by 129 bps to 300.98% in 2018, then surged by 147 bps to 142.67% in 2019.
• Per Business Quant, the three latest ATHE FCF Margin figures stand at 142.67% (Q4 2019), 300.98% (Q4 2018), and 1027.32% (Q4 2017).